Benzinga · Jul 17, 2026
Tvardi Therapeutics Increases At-The-Market Offering Program To $9.69M In Shares
- Sec Filing
TV
NASDAQ · TVRD
Tvardi Therapeutics, Inc.
Healthcare · Biotechnology
$1.14
Down-$0.06 (-5.26%)
Updated Oct 6, 2026, 10:03 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 42.12M
- P/E ratio
- -3.02
- Dividend yield
- 0.00%
- 52-week range
- $0.93 – $43.65
- Volume
- 148.92K
- Avg. volume
- 308.7K
Price performance · TVRD
TVRD price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
TVRD closed at $1.14 after 20 trading sessions, down 41.24% for the selected period.
- Last close
- $1.14
- Period change
- -41.24%
- Period low
- $1.06
- Period high
- $1.94
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.17 | $1.17 | $1.12 | $1.14 | 148.92K |
| Oct 2, 2026 | $1.25 | $1.277 | $1.13 | $1.15 | 313.81K |
| Oct 1, 2026 | $1.25 | $1.31 | $1.21 | $1.24 | 332.65K |
| Sep 30, 2026 | $1.29 | $1.32 | $1.20 | $1.25 | 232.69K |
| Sep 29, 2026 | $1.32 | $1.42 | $1.26 | $1.28 | 254.08K |
| Sep 28, 2026 | $1.27 | $1.3699 | $1.19 | $1.33 | 351.44K |
| Sep 25, 2026 | $1.14 | $1.28 | $1.07 | $1.27 | 658.22K |
| Sep 24, 2026 | $1.30 | $1.33 | $0.93 | $1.06 | 609.63K |
| Sep 23, 2026 | $1.59 | $1.61 | $1.255 | $1.32 | 412.75K |
| Sep 22, 2026 | $1.62 | $1.73 | $1.57 | $1.57 | 128.18K |
| Sep 21, 2026 | $1.65 | $1.66 | $1.57 | $1.61 | 186.73K |
| Sep 18, 2026 | $1.63 | $1.6581 | $1.59 | $1.63 | 121.59K |
| Sep 17, 2026 | $1.72 | $1.743 | $1.61 | $1.62 | 193.18K |
| Sep 16, 2026 | $1.74 | $1.805 | $1.73 | $1.73 | 126.68K |
| Sep 15, 2026 | $1.83 | $1.836 | $1.735 | $1.76 | 115.66K |
| Sep 14, 2026 | $1.89 | $2.00 | $1.81 | $1.83 | 174.15K |
| Sep 11, 2026 | $1.83 | $1.94 | $1.83 | $1.87 | 116.44K |
| Sep 10, 2026 | $1.83 | $1.90 | $1.81 | $1.835 | 77.5K |
| Sep 9, 2026 | $1.92 | $1.94 | $1.85 | $1.85 | 97.11K |
| Sep 8, 2026 | $1.91 | $1.9586 | $1.87 | $1.94 | 164.23K |
Latest TVRD news
The latest Smart Investors Daily articles mentioning TVRD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TVRD research
Overview
Company profile and research snapshot.
Company profile
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | BTIG | Buy | — |
| Jul 8, 2026 | Raymond James | Outperform | — |
| Jul 7, 2026 | BTIG | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 20, 2026 | Barclays | Underweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 9, 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences (NASDAQ:FBRX) stock rose
Benzinga · Jul 9, 2026
Why Is Tvardi Therapeutics Stock Falling Thursday?
Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for Tvardi's STAT3 prodrug TTI-109.
Benzinga · Jul 9, 2026
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stock
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
